AS1411

AS1411 is a novel aptamer-based investigational drug product currently under development and evaluation with the potential to treat viral based-infectious diseases and different types of cancers.  Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule and are typically created by selection from a large random sequence pool. The AS1411 aptamer is a G-rich oligonucleotide that targets and binds to nucleolin, a protein that is present on the surface of tumor cells.

The AS1411 aptamer has been tested as a drug in over 100 patients and is well tolerated with no evidence of severe side effects, with at least 7 patients having long-lasting clinical responses, where their cancers either disappeared or shrank substantially.

AS1411 is also a key component of Qualigen’s anti-nucleolin agent-conjugated nanoparticle drugs: ALAN, ALAN-RE and ALAN-I.